Why Hansa Biopharma’s ConfIdeS trial could reshape kidney transplant desensitization
Hansa Biopharma’s imlifidase faces a decisive FDA year as Phase 3 transplant data test whether desensitization can unlock donor access.
Hansa Biopharma files BLA for imlifidase in kidney transplant desensitization: What this changes for U.S. patients
Hansa Biopharma files for FDA approval of imlifidase to enable kidney transplants in highly sensitized patients. Find out what changes next.
How Hansa Biopharma is targeting a transplant blind spot with Imlifidase
Hansa Biopharma AB has submitted a Biologics License Application to the U.S. Food and Drug Administration for imlifidase as a desensitization treatment in highly sensitized adult patients awaiting deceased donor kidney transplants. The submission is supported by the pivotal Phase 3 ConfIdeS trial, and the company is seeking a priority review that could lead to […]